LOMBARDI, Silvia
 Distribuzione geografica
Continente #
NA - Nord America 950
EU - Europa 275
AS - Asia 190
AF - Africa 1
OC - Oceania 1
SA - Sud America 1
Totale 1.418
Nazione #
US - Stati Uniti d'America 947
IT - Italia 123
CN - Cina 114
DE - Germania 46
TR - Turchia 32
SE - Svezia 23
UA - Ucraina 22
GB - Regno Unito 16
HK - Hong Kong 10
PL - Polonia 10
IR - Iran 9
JP - Giappone 7
BE - Belgio 6
FR - Francia 6
NO - Norvegia 6
FI - Finlandia 5
CA - Canada 3
DK - Danimarca 3
IN - India 3
KR - Corea 3
PT - Portogallo 3
GE - Georgia 2
IL - Israele 2
RO - Romania 2
TW - Taiwan 2
VN - Vietnam 2
AT - Austria 1
AU - Australia 1
BR - Brasile 1
CH - Svizzera 1
ID - Indonesia 1
IQ - Iraq 1
MY - Malesia 1
NL - Olanda 1
PK - Pakistan 1
RU - Federazione Russa 1
ZA - Sudafrica 1
Totale 1.418
Città #
Chandler 177
Fairfield 103
Ashburn 56
Ferrara 50
Woodbridge 50
Houston 43
Ann Arbor 41
Cambridge 36
New York 36
Seattle 35
Princeton 34
Wilmington 34
Izmir 27
Milan 24
Beijing 21
Bremen 21
Jacksonville 20
Shanghai 20
Nanjing 19
Redwood City 13
Dearborn 11
Los Angeles 10
Warsaw 10
Ferrara di Monte Baldo 8
Hebei 8
San Diego 7
Bologna 5
Brussels 5
Guangzhou 5
Hong Kong 5
Piemonte 5
Cagliari 4
Chicago 4
Nanchang 4
Rochester 4
San Mateo 4
Shenyang 4
Copenhagen 3
Helsinki 3
Jiaxing 3
Norwalk 3
Oslo 3
Racale 3
Silveira 3
Tianjin 3
Toronto 3
Washington 3
Zhengzhou 3
Andover 2
Augusta 2
Belvedere Spinello 2
Boardman 2
Changsha 2
Cheltenham 2
Des Moines 2
Dong Ket 2
Duncan 2
Falls Church 2
Hangzhou 2
Henderson 2
Ithaca 2
Jinan 2
Kunming 2
Leawood 2
London 2
Monmouth Junction 2
Ningbo 2
Sabz 2
Semnan 2
Tabriz 2
Tel Aviv 2
Worcester 2
Balk 1
Bhubaneswar 1
Bloemfontein 1
Boxborough 1
Cento 1
Central District 1
Chengdu 1
Chongqing 1
Dallas 1
Danvers 1
Dortmund 1
Emden 1
Esslingen am Neckar 1
Falkenstein 1
Fars 1
Glenside 1
Grugliasco 1
Haikou 1
Hefei 1
Hounslow 1
Hyderabad 1
Imola 1
Islamabad 1
Kanpur 1
Louvain 1
Modesto 1
Moscow 1
Mountain View 1
Totale 1.072
Nome #
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency 158
Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context 120
The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation 105
The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies 98
Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants 72
The carboxyl-terminal region of human coagulation factor X as a novel naturally-occuring linker for fusion strategies 66
A strategy with chaperone-like compounds to restore expression of factor IX variants affected by frequent missense mutations causing hemophilia B 59
A Compensatory U1snRNA Partially Rescues FAH Splicing and Protein Expression in a Splicing-Defective Mouse Model of Tyrosinemia Type I 55
The chaperone-like compound sodium phenylbutyrate improves intracellular trafficking, secretion and coagulant activity of factor IX impaired by the frequent p.R294Q mutation 54
Exploring chaperone-like compounds as innovative therapeutic correction approach for factor IX missense mutations causing type I Haemophilia B 50
A next-generation rFVIIa fusion protein with enhanced half-life as a novel by-passing tool in hemophilia 47
Exon-Specific U1snRNA-Mediated Rescue of Splicing and Missense Changes in Hemophilia A 46
An exon-specific small nuclear u1 rna (Exspeu1) improves hepatic otc expression in a splicing-defective spf /ash mouse model of ornithine transcarbamylase deficiency 45
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics 45
Exploring spontaneous readthrough over recurrent F8 nonsense mutations: potential correlation with inhibitor risk? 44
Rational engineering of a novel factor IX albumin fusion protein results in enhanced coagulant activity and pharmacokinetic profile 43
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity 43
Exploring chaperone-like compounds as innovative therapeutic strategy for Hemophilia B 40
Readthrough-mediated functional suppression of homozygous nonsense mutations accounts for variable bleeding phenotypes in factor VII deficiency 38
Design of a novel factor IX albumin fusion protein with enhanced coagulant activity and pharmacokinetic profile 37
Dissection of pleiotropic effects of variants in and adjacent to F8 exon 19 and rescue of mRNA splicing and protein function 35
Detection of Residual Factor VIII Levels Reveals the Occurrence of Readthrough Over the Majority of F8 Nonsense Mutations 34
Molecular insights into determinants of translational readthrough and implications for nonsense suppression approaches 33
Spontaneous readthrough over recurrent F8 nonsense mutations is associated with residual factor VIII levels: implications for inhibitor risk? 29
Design of a novel factor IX variant with enhanced procoagulant activity and half-life 28
Deep molecular mechanisms of F8 exon 19 variants and translational approaches in Hemophilia A 23
Rescue of multiple Haemophilia A-causing mutations by a single ExSpeU1: the importance of the genomic context 20
Translation termination codons in protein synthesis and disease 17
Targeted molecular strategies for X-linked genetic disorders: the paradigmatic models of Fabry disease and Haemophilias 17
Translational readthrough at F8 nonsense variants in the factor VIII B domain contributes to residual expression and lowers inhibitor association 15
Comparative Analysis Of Residual Factor VIII Expression from Recurrent F8 Nonsense Mutations Indicates that Localization in the B- domain Favours Readthrough- mediated Protein Output 13
Totale 1.529
Categoria #
all - tutte 8.335
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 114
Totale 8.449


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201975 0 0 0 0 0 0 0 0 0 0 17 58
2019/2020223 36 8 13 30 23 27 23 19 20 10 9 5
2020/2021242 7 5 9 14 13 28 31 46 9 21 32 27
2021/2022280 52 34 10 4 20 14 7 7 8 20 19 85
2022/2023372 30 49 10 53 55 38 30 22 52 3 17 13
2023/2024163 9 21 12 4 13 49 9 23 8 15 0 0
Totale 1.529